share_log

BeyondSpring's Lead Cancer Drug Protects Bone Marrow Stem Cells Within 24 Hours

BeyondSpring's Lead Cancer Drug Protects Bone Marrow Stem Cells Within 24 Hours

萬春醫藥的抗癌先導藥物在24小時內保護骨髓幹細胞
Benzinga Real-time News ·  2022/09/13 09:58
  • BeyondSpring Inc (NASDAQ:BYSI) announced data from a poster presentation at the ESMO Congress 2022, including a new analysis from the Phase 2/3 PROTECTIVE-1 and PROTECTIVE-2 trials of plinabulin.
  • Plinabulin, the company's lead asset, is a selective immunomodulating microtubule-binding agent, a potent antigen-presenting cell (APC) inducer being developed as an anticancer agent.
  • Related: BeyondSpring Presents New Data From Lead Asset On Neutropenia In Multiple Myeloma Patients.
  • The data provides evidence of protection of bone marrow granulocyte-monocyte progenitor (GMP) stem cells within 24 hours after chemotherapy based on an evaluation of peripheral immature and mature neutrophil counts.
  • The absolute neutrophil count (ANC) with and without plinabulin was comparable at pre-dose C1D1 (p=0.96) but was significantly higher at 24 hours post-chemo dose with plinabulin vs. control.
  • At 24 hours post-chemo dose, the mean ANC had increased by 3.2 x 109/L with plinabulin, whereas the mean ANC had decreased by 0.55 x 109/L with the control due to the myelosuppressive effect of TAC chemotherapy.
  • Price Action: BYSI shares are down 0.47% at $1.52 on the last check Tuesday.
  • 萬春醫藥納斯達克(Sequoia Capital：BYSI)宣佈了2022年歐洲藥品監督管理局大會海報演示中的數據，包括對普利布林2/3期保護性1和保護性2試驗的新分析。
  • 普利布林是該公司的主要資產，是一種選擇性免疫調節微管結合劑，是一種正在開發的作為抗癌劑的有效抗原提呈細胞(APC)誘導劑。
  • 相關： 萬春醫藥公佈了Lead Asset關於多發性骨髓瘤患者中性粒細胞減少症的新數據.
  • 根據對外周血未成熟和成熟中性粒細胞計數的評估，這些數據提供了化療後24小時內骨髓粒-單核細胞祖細胞(GMP)幹細胞保護的證據。
  • 中性粒細胞絕對計數(ANC)在用藥前和用藥前相似(p=0.96)，但化療後24小時用藥組明顯高於對照組。
  • 在化療後24小時，平均ANC增額普利布林3.2×109/L，而平均ANC減少由於TAC化療的骨髓抑制作用，與對照組相比增加0.55×109/L。
  • 價格行動：比亞迪股價週二尾盤下跌0.47%，至1.52美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論